Datar Cancer Genetics recently announced an association with Kokilaben Dhirubhai Ambani Hospital, Mumbai to bring their series of unique revolutionary blood tests for early and easy detection of cancer. The first-of-its-kind range of cancer screening tests include EasyCheck360 and EasyCheck Femmesafe. Coming soon after World Cancer Day, the EasyCheck cancer tests will help in early detection of cancer that is critical for successful treatment and cure. These easy blood tests overcome the challenges of conventional cancer screening procedures that are invasive and resource intensive.
“Cancer has become a chronic disease and one which can be treated successfully if detected early. The key to beating cancer is screening and early detection. Early detection will lead to a high chance of survival in most cases. EasyCheck360 is a breakthrough test and will go a long way in helping witness a cancer free India,” said Samara Mahindra, Director, New Cancer Initiatives, Datar Cancer Genetics.
“Cancer is one of the leading causes of death from non-communicable diseases. While early detection helps in increasing the chances of a faster recovery, studies have shown that the majority of cancers were diagnosed at an advanced stage. Only a low proportion presents in the early stages. Creating awareness about the need for early detection of cancer and the availability of easy, simple tests for the same would help in catching cancer early. We are glad to offer the EasyCheck range of cancer tests that will go a long way in battling the dreaded disease of cancer,” said Dr. Santosh Shetty, Executive Director and CEO, Kokilaben Dhirubhai Ambani Hospital.
The EasyCheck360, EasyCheck Femmesafe and EasyCheck Prostrate are early cancer screening tests that detect the existence of cancer. The EasyCheck360 is not a genetic predisposition test and is a real time test. The test also indicates the location for the select types of cancers with high accuracy, and in others the Tissue of Origin can be identified. A ‘positive’ result is interpreted by the oncologist for further course of action. The early detection will result in higher chance of recovery and survival, minimal treatment cost and better quality of life.
As these are non-invasive blood tests, there is no disadvantage in frequent testing. However, it is advised that EasyCheck360 should be performed every 12 months in case of a negative result for individuals over the age of 30 years. EasyCheck360 gives people an easy and reliable way of taking control of their health. The test also enables cancer screening to be a part of the annual health check-up routine, with an opportunity to treat the disease at an early stage if detected without the burden of cost, extreme physical and psychological discomfort coupled with a very good chance of survival.
These multi-cancer screening tests have undergone one of the largest trials registered under the WHO, to establish a definitive new systemic hallmark of cancer. The technique employed is a proprietary technology which is a pathbreaking innovation, designed to detect circulating tumour cells (CTC) and their clusters before they become symptomatic or clinically detectable. The tests analyse CTC in the peripheral blood of an individual, are intended to detect the presence of malignant cells and have been clinically proven to have an accuracy of greater than 99% in detecting cancer early.
Patients can contact Kokilaben Dhirubhai Ambani Hospital for the tests. These tests are for women and men of age 30 years and above and are not suitable for pregnant women, cancer patients, individuals with symptoms of cancer and those with a previous history of cancer. For individuals below 30 years of age, a prescription from a medical practitioner is required.
There are 2 tests that are currently available at Kokilaben Dhirubhai Ambani Hospital:
● EasyCheck360®: this one is intended to be performed annually as a screening test on individuals aged 30 years and above without any symptoms suggestive of cancer. It screens for about 30 types of cancer.
● EasyCheck – FemmeSafe: this one is intended to be performed annually as a screening test on women aged 30 years and above without any symptoms suggestive of cancer. It screens for 4 types of cancer.